Effective engineering of a ketoreductase for the biocatalytic synthesis of an ipatasertib precursor.


Journal

Communications chemistry
ISSN: 2399-3669
Titre abrégé: Commun Chem
Pays: England
ID NLM: 101725670

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 25 08 2023
accepted: 15 02 2024
medline: 29 2 2024
pubmed: 29 2 2024
entrez: 28 2 2024
Statut: epublish

Résumé

Semi-rational enzyme engineering is a powerful method to develop industrial biocatalysts. Profiting from advances in molecular biology and bioinformatics, semi-rational approaches can effectively accelerate enzyme engineering campaigns. Here, we present the optimization of a ketoreductase from Sporidiobolus salmonicolor for the chemo-enzymatic synthesis of ipatasertib, a potent protein kinase B inhibitor. Harnessing the power of mutational scanning and structure-guided rational design, we created a 10-amino acid substituted variant exhibiting a 64-fold higher apparent k

Identifiants

pubmed: 38418529
doi: 10.1038/s42004-024-01130-5
pii: 10.1038/s42004-024-01130-5
doi:

Types de publication

Journal Article

Langues

eng

Pagination

46

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 180544

Informations de copyright

© 2024. The Author(s).

Références

Patel, R. N. Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals. Biomolecules 3, 741–777 (2013).
pubmed: 24970190 pmcid: 4030968 doi: 10.3390/biom3040741
Hashiguchi, S. et al. Kinetic resolution of racemic secondary alcohols by Ru(II)-catalyzed hydrogen transfer. Angew. Chem. Int. Ed. 36, 288–290 (1997).
doi: 10.1002/anie.199702881
Noyori, R. Asymmetric catalysis: science and opportunities (Nobel Lecture 2001). Adv. Synth. Catal. 345, 15–32 (2003).
doi: 10.1002/adsc.200390002
Klingler, F. D. Asymmetric hydrogenation of prochiral amino ketones to amino alcohols for pharmaceutical use. Acc. Chem. Res. 40, 1367–1376 (2007).
pubmed: 18052332 doi: 10.1021/ar700100e
Bornscheuer, U. T. et al. Engineering the third wave of biocatalysis. Nature 485, 185–194 (2012).
pubmed: 22575958 doi: 10.1038/nature11117
Rodriguez, S. et al. Amine‐tunable ruthenium catalysts for asymmetric reduction of ketones. Adv. Synth. Catal. 356, 301–307 (2014).
doi: 10.1002/adsc.201300727
Hayler, J. D., Leahy, D. K. & Simmons, E. M. A pharmaceutical industry perspective on sustainable metal catalysis. Organometallics 38, 36–46 (2019).
doi: 10.1021/acs.organomet.8b00566
Seo, C. S. G. & Morris, R. H. Catalytic homogeneous asymmetric hydrogenation: successes and opportunities. Organometallics 38, 47–65 (2019).
doi: 10.1021/acs.organomet.8b00774
Wu, S., Snajdrova, R., Moore, J. C., Baldenius, K. & Bornscheuer, U. T. Biocatalysis: enzymatic synthesis for industrial applications. Angew. Chem. Int. Ed. 60, 88–119 (2021).
doi: 10.1002/anie.202006648
Buller, R. et al. From nature to industry: harnessing enzymes for biocatalysis. Science 382, eadh8615 (2023).
pubmed: 37995253 doi: 10.1126/science.adh8615
Huisman, G. W., Liang, J. & Krebber, A. Practical chiral alcohol manufacture using ketoreductases. Curr. Opin. Chem. Biol. 14, 122–129 (2010).
pubmed: 20071211 doi: 10.1016/j.cbpa.2009.12.003
Buller, R., Hecht, K., Mirata, M. A. & Meyer, H.-P. An appreciation of biocatalysis in the Swiss manufacturing environment. in Biocatalysis: An Industrial Perspective (eds de Gonzalo, G. & Domínguez de María, P.) 3–43 (The Royal Society of Chemistry, 2017).
Jez, J. M., Bennett, M. J., Schlegel, B. P., Lewis, M. & Penning, T. M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 326, 625–636 (1997).
pubmed: 9307009 pmcid: 1218714 doi: 10.1042/bj3260625
Hughes, D. L. Biocatalysis in drug development—highlights of the recent patent literature. Org. Process Res. Dev. 22, 1063–1080 (2018).
doi: 10.1021/acs.oprd.8b00232
Ma, S. K. et al. A green-by-design biocatalytic process for atorvastatin intermediate. Green. Chem. 12, 81–86 (2010).
doi: 10.1039/B919115C
Gong, X. M. et al. Development of an engineered ketoreductase with simultaneously improved thermostability and activity for making a bulky atorvastatin precursor. ACS Catal. 9, 147–153 (2019).
doi: 10.1021/acscatal.8b03382
Liang, J. et al. Development of a biocatalytic process as an alternative to the (-)-DIP-Cl-mediated asymmetric reduction of a key intermediate of montelukast. Org. Process Res. Dev. 14, 193–198 (2010).
doi: 10.1021/op900272d
Depré, D. P. M. et al. Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV. US20180093943A1 (2018).
Slagman, S. & Fessner, W. D. Biocatalytic routes to anti-viral agents and their synthetic intermediates. Chem. Soc. Rev. 50, 1968–2009 (2021).
pubmed: 33325938 doi: 10.1039/D0CS00763C
Han, C. et al. Asymmetric synthesis of Akt kinase inhibitor ipatasertib. Org. Lett. 19, 4806–4809 (2017).
pubmed: 28858516 doi: 10.1021/acs.orglett.7b02228
Bachmann, S. et al. Development of the commercial manufacturing process for ipatasertib. CHIMIA 75, 605–613 (2021).
pubmed: 34523401 doi: 10.2533/chimia.2021.605
Blake, J. F. et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J. Med. Chem. 55, 8110–8127 (2012).
Shi, Z. et al. Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 38, 182 (2020).
doi: 10.1200/JCO.2020.38.6_suppl.182
Dent, R. et al. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Breast Cancer Res. Treat. 189, 377–386 (2021).
pubmed: 34264439 doi: 10.1007/s10549-021-06143-5
Eichenberger, M. et al. Asymmetric cation‐olefin monocyclization by engineered squalene hopene cyclases. Angew. Chem. Int. Ed. 60, 26080–26086 (2021).
doi: 10.1002/anie.202108037
Meyer, F. et al. Modulating chemoselectivity in a Fe(II)/α-ketoglutarate-dependent dioxygenase for the oxidative modification of a nonproteinogenic amino acid. ACS Catal. 11, 6261–6269 (2021).
doi: 10.1021/acscatal.1c00678
Papadopoulou, A., Peters, C., Borchert, S., Steiner, K. & Buller, R. Development of an Ene reductase-based biocatalytic process for the production of flavor compounds. Org. Process Res. Dev. 26, 2102–2110 (2022).
doi: 10.1021/acs.oprd.2c00096
Voss, M. et al. Multi-faceted set-up of a diverse ketoreductase library enables the synthesis of pharmaceutically-relevant secondary alcohols. ChemCatChem 13, 1538–1545 (2021).
doi: 10.1002/cctc.202001871
Kita, K., Nakase, K. I., Yanase, H., Kataoka, M. & Shimizu, S. Purification and characterization of new aldehyde reductases from Sporobolomyces salmonicolor AKU4429. J. Mol. Catal. B Enzym. 6, 305–313 (1999).
doi: 10.1016/S1381-1177(98)00108-8
Kita, K. et al. Cloning, overexpression, and mutagenesis of the Sporobolomyces salmonicolor AKU4429 gene encoding a new aldehyde reductase, which catalyzes the stereoselective reduction of ethyl 4-chloro-3-oxobutanoate to ethyl (S)-4-chloro-3-hydroxybutanoate. Appl. Environ. Microbiol. 65, 5207–5211 (1999).
pubmed: 10583966 pmcid: 91706 doi: 10.1128/AEM.65.12.5207-5211.1999
Kamitori, S., Iguchi, A., Ohtaki, A., Yamada, M. & Kita, K. X-ray structures of NADPH-dependent carbonyl reductase from Sporobolomyces salmonicolor provide insights into stereoselective reductions of carbonyl compounds. J. Mol. Biol. 352, 551–558 (2005).
pubmed: 16095619 doi: 10.1016/j.jmb.2005.07.011
Zhu, D. et al. Inverting the enantioselectivity of a carbonyl reductase via substrate-enzyme docking-guided point mutation. Org. Lett. 10, 525–528 (2008).
pubmed: 18205368 doi: 10.1021/ol702638j
Li, H., Zhu, D., Hua, L. & Biehl, E. R. Enantioselective reduction of diaryl ketones catalyzed by a carbonyl reductase from Sporobolomyces salmonicolor and its mutant enzymes. Adv. Synth. Catal. 351, 583–588 (2009).
doi: 10.1002/adsc.200900045
Li, H., Yang, Y., Zhu, D., Hua, L. & Kantardjieff, K. Highly enantioselective mutant carbonyl reductases created via structure-based site-saturation mutagenesis. J. Org. Chem. 75, 7559–7564 (2010).
pubmed: 20964397 doi: 10.1021/jo101541n
Li, J. et al. Structure-guided directed evolution of a carbonyl reductase enables the stereoselective synthesis of (2S,3S)-2,2-disubstituted-3-hydroxycyclopentanones via desymmetric reduction. Org. Lett. 22, 3444–3448 (2020).
pubmed: 32319785 doi: 10.1021/acs.orglett.0c00892
Iding, H., Reents, R., Scalone, M. & Gosselin, F. Processes for the preparation of pyrimidinylcyclopentane compounds. US20160297773A1 (2016).
Büchler, J. et al. Algorithm-aided engineering of aliphatic halogenase WelO5* for the asymmetric late-stage functionalization of soraphens. Nat. Commun. 13, 371 (2022).
pubmed: 35042883 pmcid: 8766452 doi: 10.1038/s41467-022-27999-1
Kawashima, S. & Kanehisa, M. AAindex: amino acid index database. Nucleic Acids Res. 28, 374 (2000).
pubmed: 10592278 pmcid: 102411 doi: 10.1093/nar/28.1.374
Kawashima, S. et al. AAindex: amino acid index database, progress report 2008. Nucleic Acids Res. 36, 202–205 (2008).
doi: 10.1093/nar/gkm998
Saito, Y. et al. Machine-learning-guided library design cycle for directed evolution of enzymes: the effects of training data composition on sequence space exploration. ACS Catal. 11, 14615–14624 (2021).
doi: 10.1021/acscatal.1c03753
Lu, H. et al. Machine learning-aided engineering of hydrolases for PET depolymerization. Nature 604, 662–667 (2022).
pubmed: 35478237 doi: 10.1038/s41586-022-04599-z
Ma, E. J. et al. Machine-directed evolution of an imine reductase for activity and stereoselectivity. ACS Catal. 11, 12433–12445 (2021).
doi: 10.1021/acscatal.1c02786
Vornholt, T. et al. Systematic engineering of artificial metalloenzymes for new-to-nature reactions. Sci. Adv. 7, 1–12 (2021).
doi: 10.1126/sciadv.abe4208
Greenhalgh, J. C., Fahlberg, S. A., Pfleger, B. F. & Romero, P. A. Machine learning-guided acyl-ACP reductase engineering for improved in vivo fatty alcohol production. Nat. Commun. 12, 1–10 (2021).
doi: 10.1038/s41467-021-25831-w
Romero, P. A., Krause, A. & Arnold, F. H. Navigating the protein fitness landscape with Gaussian processes. Proc. Natl Acad. Sci. USA 110, E193–E201 (2013).
pubmed: 23277561 doi: 10.1073/pnas.1215251110
Domínguez de María, P. Biocatalysis, sustainability, and industrial applications: show me the metrics. Curr. Opin. Green Sustain. Chem. 31, 100514 (2021).
doi: 10.1016/j.cogsc.2021.100514
Reetz, M. T. & Carballeira, J. D. Iterative saturation mutagenesis (ISM) for rapid directed evolution of functional enzymes. Nat. Protoc. 2, 891–903 (2007).
pubmed: 17446890 doi: 10.1038/nprot.2007.72
Banta, S., Swanson, B. A., Wu, S., Jarnagin, A. & Anderson, S. Alteration of the specificity of the cofactor-binding pocket of Corynebacterium 2,5-diketo-D-gluconic acid reductase A. Protein Eng. 15, 131–140 (2002).
pubmed: 11917149 doi: 10.1093/protein/15.2.131
Kokkonen, P., Bednar, D., Pinto, G., Prokop, Z. & Damborsky, J. Engineering enzyme access tunnels. Biotechnol. Adv. 37, 107386 (2019).
pubmed: 31026496 doi: 10.1016/j.biotechadv.2019.04.008
Yang, K. K., Wu, Z. & Arnold, F. H. Machine-learning-guided directed evolution for protein engineering. Nat. Methods 16, 687–694 (2019).
pubmed: 31308553 doi: 10.1038/s41592-019-0496-6
Reetz, M. T. The importance of additive and non‐additive mutational effects in protein engineering. Angew. Chem. Int. Ed. 52, 2658–2666 (2013).
doi: 10.1002/anie.201207842
Mazurenko, S., Prokop, Z. & Damborsky, J. Machine learning in enzyme engineering. ACS Catal. 10, 1210–1223 (2020).
doi: 10.1021/acscatal.9b04321
Hie, B., Bryson, B. D. & Berger, B. Leveraging uncertainty in machine learning accelerates biological discovery and design. Cell Syst. 11, 461–477.e9 (2020).
pubmed: 33065027 doi: 10.1016/j.cels.2020.09.007
Wittmann, B. J., Johnston, K. E., Wu, Z. & Arnold, F. H. Advances in machine learning for directed evolution. Curr. Opin. Struct. Biol. 69, 11–18 (2021).
pubmed: 33647531 doi: 10.1016/j.sbi.2021.01.008
Hie, B. L. & Yang, K. K. Adaptive machine learning for protein engineering. Curr. Opin. Struct. Biol. 72, 145–152 (2022).
pubmed: 34896756 doi: 10.1016/j.sbi.2021.11.002
Markus, B. et al. Accelerating biocatalysis discovery with machine learning: a paradigm shift in enzyme engineering, discovery, and design. ACS Catal. 13, 14454–14469 (2023).
pubmed: 37942268 pmcid: 10629211 doi: 10.1021/acscatal.3c03417
Patsch, D. & Buller, R. Improving enzyme fitness with machine learning. CHIMIA 77, 116–121 (2023).
pubmed: 38047813 doi: 10.2533/chimia.2023.116
Chen, X., Zhang, H., Feng, J., Wu, Q. & Zhu, D. Molecular basis for the high activity and enantioselectivity of the carbonyl reductase from Sporobolomyces salmonicolor toward α-Haloacetophenones. ACS Catal. 8, 3525–3531 (2018).
doi: 10.1021/acscatal.8b00591
Kille, S. et al. Reducing codon redundancy and screening effort of combinatorial protein libraries created by saturation mutagenesis. ACS Synth. Biol. 2, 83–92 (2013).
pubmed: 23656371 doi: 10.1021/sb300037w
Xia, Y. et al. T5 exonuclease-dependent assembly offers a low-cost method for efficient cloning and site-directed mutagenesis. Nucleic Acids Res. 47, 1–11 (2019).
doi: 10.1093/nar/gky1169
Miyazaki, K. & Takenouchi, M. Creating random mutagenesis libraries using PCR of whole plasmid. Biotechniques 33, 1033–1034 (2002).
pubmed: 12449380 doi: 10.2144/02335st03
Rasmussen, C. E. & Williams, C. K. I. Gaussian processes for machine learning. In Advanced Lectures on Machine Learning: ML Summer Schools (eds Bousquet, O., von Luxburg, U. & Raetsch, G.) (MIT, 2006).
Molecular Operating Environment (MOE), 2019.01. (Chemical Computing Group ULC, 2019).
Gerber, P. R. & Müller, K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J. Comput. Aided Mol. Des. 9, 251–268 (1995).
pubmed: 7561977 doi: 10.1007/BF00124456
Letunic, I. & Bork, P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 49, W293–W296 (2021).
pubmed: 33885785 pmcid: 8265157 doi: 10.1093/nar/gkab301

Auteurs

Sumire Honda Malca (S)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.

Nadine Duss (N)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.

Jasmin Meierhofer (J)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.
Analytical Research and Development, MSD Werthenstein BioPharma GmbH, Industrie Nord 1, 6105 Schachen, Switzerland.

David Patsch (D)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.

Michael Niklaus (M)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.

Stefanie Reiter (S)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.
Manufacturing Science and Technology, Fisher Clinical Services GmbH, Biotech Innovation Park, 2543 Lengnau, Switzerland.

Steven Paul Hanlon (SP)

Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.

Dennis Wetzl (D)

Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
Nonclinical Drug Development, Boehringer Ingelheim International GmbH, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Bernd Kuhn (B)

Pharmaceutical Research and Early Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.

Hans Iding (H)

Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.

Rebecca Buller (R)

Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland. rebecca.buller@zhaw.ch.

Classifications MeSH